



Knowledge Regarding Breast Cancer and Its Management

Ms Uma Ranga^{1*}, Dr. Sumit Padihar²

¹Ph.D Scholar, Mansarovar Global University, Bhopal, Madhya Pradesh

²Research Supervisor, Mansarovar Global University, Bhopal, Madhya Pradesh

*Corresponding Author: - Ms Uma Ranga

*Ph.D Scholar, Mansarovar Global University, Bhopal, Madhya Pradesh

KEYWORDS:

knowledge and breast cancer.

ABSTRACT

As the most frequent tumour worldwide, breast cancer continues to be a global public health concern. Breast cancer detection and screening have improved as a result of increased public awareness of the disease, increased attention from the general population, and advancements in breast imaging. Breast cancer is the most common cause of death for women and a potentially fatal illness for women. Over the past 20 years, research on breast cancer has led to a remarkable progress in our knowledge of the disease and the development of more effective treatments. With breast cancer accounting for 23% of all cancer-related deaths in postmenopausal women, it is one of the most common malignant diseases overall. This is a worldwide problem now, but because women are so careless when it comes to self-examination and professional breast exams, the disease is still detected in its advanced stages. The structure of the breast, risk factors, epidemiology, pathogenesis, and stages of breast cancer are all covered in this review. Additionally, breast cancer treatment options include radiation therapy, chemotherapy, surgery, targeted therapies, hormone replacement therapy, chemotherapy, complementary therapies, gene therapy, and stem cell therapy.

Background of the study

In women worldwide, breast cancer is the most prevalent type of cancer and the leading cause of cancer-related death. In 2008, there were over 1.38 million new cases of breast cancer diagnosed; nearly 50% of these patients also died from the disease, and about 60% of these fatalities occurred in developing nations. Globally, the 5-year survival rate for breast cancer varies greatly; in developed countries, it is expected to be 80%, whereas in developing countries, it is less than 40%. Infrastructure and resource limitations in developing nations make it difficult to achieve the goal of improving breast cancer outcomes through early detection, diagnosis, and treatment. In wealthy nations such as the United States, 39,620 women will die and approximately 232,340 women will receive a diagnosis of breast cancer in 2013. For American women, the lifetime risk of breast cancer is 12.38%. The considerable reduction in mortality brought on by breast cancer in the United States between 1975 and 2000 is ascribed to continuous improvements in mammography screening as well as management. The World Health Organisation (WHO) states that the cornerstone of breast cancer regulations continues to be improving breast cancer outcome and survival through early detection. To treat breast cancer,

various contemporary medications are recommended. Antiestrogens like raloxifene or tamoxifen used in medical therapy for breast cancer may prevent the disease in those who are more susceptible to it. In addition to other preventative measures, surgery on both breasts is recommended for women who have an elevated risk of acquiring cancer. Various care options, including hormonal therapy, radiation therapy, surgery, chemotherapy, and targeted therapy, are employed for individuals diagnosed with breast tumours. The goal of care for patients with distant metastases is usually to improve the quality of life and survival rate. One of the main reasons people look for alternative treatments for breast cancer is the terrible side effects of the disease. Because certain plants may naturally have the power to treat breast cancer, using herbs to treat people with the disease is regarded as a natural option.

Epidemiology

In Britain today, breast cancer affects one in twelve females between the ages of one and eighty-five. Breast cancer is prevalent in females and accounts for 18% of all cancer incidences in women, with one million new instances of the disease recorded worldwide. By 2021, the incidence of breast cancer is expected to rise to 85 cases per 100,000 women. One



in every five female cancer cases was diagnosed as breast cancer in 2012, with 1.67 million new cases reported. According to Ferlay et al., 794,000 instances occur in the majority of wealthy countries, while 883,000 cases occur in less developed nations. Based on available statistics, 66.3 women in Poland and 145.2 women in Belgium per 100,000 have breast cancer. In the United States, one in eight women will have breast cancer, but in Asia, one in 35 women will develop the disease. Ten cases for every 100,000 people live in Iran, and 7,000 new cases are reported there each year. In Pakistan, the prevalence of breast cancer is rising. The majority of cases of breast cancer occur in densely populated South Asian developing nations. Male breast cancer cases have been identified in Pakistan's northern regions. According to Yang et al., there were 168,013 new cases of breast cancer in China in 2005 compared to 121,269 cases in 2000.

Causative and risk factors of breast carcinoma

For British women between the ages of 40 and 55, breast cancer is the primary cause of mortality. Compared to married women, unmarried women are more likely to develop breast cancer. An organ responsive to oestrogen is the breast. Many women who have used oestrogen replacement therapy or birth control tablets have discovered that the drugs cause their breasts to swell and frequently become painful. Breast cancer may be triggered by the interaction between this medication's activity and the typical western diet of high fat and low fibre, which overstimulates breast tissue. Women over 50 have a greater incidence of breast cancer—2 cases out of every 1000 are reported in this age range. It is most frequent for women with breast cancer to experience depression. A study on breast, cervical, and colorectal cancer knowledge was carried out by Andsoy et al. A total of 226 active nurses were screened for this investigation. Finding that women who give birth before the age of twenty are known to have a lower risk of breast cancer than women who have never given birth or who give birth to their first child after the age of thirty is an intriguing finding from certain epidemiological studies. In the premenopausal stage, the risk rises quickly with age, while in the postmenopausal stage, it climbs more slowly. Breastfeeding lowers the chance of developing breast cancer. Breast cancer is more common as people age, but it is rarely discovered before the age of 20. A single breast cancer can quadruple the risk of developing another breast cancer. Patients with a history of colon, endometrial, or ovarian cancer are at a 1-2 times higher risk of developing breast cancer. A

woman who has experienced breast cancer is more likely to develop the disease in her other breast. It has been determined that the gene plays a limited impact in the onset of breast cancer. About 5–10% of breast cancers that are passed down from mothers to their children are thought to be caused by the BRCA-1 (breast cancer susceptibility gene).

Pathogenesis of breast cancer

The breasts are intricate tubulo-alveolar organs that undergo a series of changes from reproductive age to senescence. They are embedded in asymmetrical connective tissue. The alterations seen throughout each menstrual cycle and pregnancy led us to surmise that precursor cells capable of synthesising unique duct-lobular units exist in mature tissue. A stratified epithelium surrounded by a basement membrane and embedded in a pattern of lymphatic, stromal, and blood arteries makes up the normal breast architecture. The stratified epithelium of the normal breast is made up of two distinct cell populations: myoepithelial and epithelial. These can be identified through immunohistochemistry staining using antibodies against myosin and CK, respectively. There is a theory that suggests the basic developmental sequence of the normal breast determines the formation of cellular heterogeneity in breast diseases. The heterogeneity of breast cancer may result from a neoplastic alteration of either myoepithelial or epithelial cells, or alternatively, from a stem cell with the capacity to differentiate into any of these cell types. Breast cancer oncology states that neoplastic cells are not the same as normal body cells. The body's normal tissues have minimal growth encouragement and regulation, which maintains the tissues' regular form and functioning. Nonetheless, malignant cells proliferate continuously and for a long time in the absence of external stimuli. The genes that restrict growth are overcome by cancer cells. A malignant condition that starts in the breast cells is called breast cancer. Breast cancer is a tumour that can arise from a variety of sources, just like other malignant tumours. Exposure to oestrogen has been linked to genetic alterations and damage to the deoxyribonucleic acid (DNA), which can lead to breast cancer. Certain patients are born with genetic defects in genes such as P53, BRCA1, and BRCA2, as well as in deoxyribonucleic acid (DNA). Patients who have a family history of ovarian or breast cancer are at an increased risk of acquiring breast cancer. For neoplastic cells to proliferate and grow into a large tumour, they need a lot of potential. Normally, the immune system searches for and destroys cancerous cells as well as cells with damaged deoxyribonucleic



acid (DNA). A breakdown of such a helpful immune defence and surveillance system could lead to breast cancer. Genetic and environmental factors are frequently linked to the development of breast cancer. Normal cells are protected from cell suicide via the PI3K/AKT pathway and the RAS/MEK/ERK pathway. Cancer develops as a result of mutations in the genes responsible for encoding these protective processes, which prevents cells from killing themselves when they are no longer needed. It was established through experimentation that these alterations were connected to oestrogen exposure. It was suggested that malignant cell proliferation could be aided by deformities in the growth factor signalling. The overexpression of leptin in breast adipose tissue promotes cancerous cell growth. There are several growth factors, signalling molecules, and other variables that influence the interactions between stromal and epithelial cells. A break in them could lead to the development of breast cancer. The telomerase enzyme prevents chromosomal shortening in cancer cells, enabling massive cell reproduction. Angiogenesis provides nutrition and oxygen to tumour cells. In order to create a secondary tumour, cancer cells can breach their boundaries and invade the bloodstream, lymphatic tissues, and other bodily tissues.

Diagnosis

History and physical examination

The goal of a patient's clinical history is to demonstrate the presence or absence of symptoms suggestive of breast sickness and to look into the cancer threat. Age at menarche, menopausal state, earlier pregnancies, usage of hormone replacement treatment following menopause, and use of oral contraceptives must all be included. Both family and personal histories should be thoroughly investigated. Personal history includes age at breast cancer diagnosis, prior breast biopsies, and radiation treatment for other cancers. First-degree relatives' medical histories include records of ovarian and breast cancer.

Self-examination-

The benefit of breast self-examination in terms of fewer deaths has not been shown, making its usefulness debatable. The majority of doctors train women to perform monthly BSE so that they may be identified by their typical structure and given permission based on their own medical needs. Women are given guidance on how to self-examine for breast cancer. When women self-examine, they can discover anomalies in the size and contour of their breasts.

Ultrasound breast imaging

The use of adjunctive screening ultrasonography in women with thick breast tissue who are at elevated risk is supported by a number of studies, and the number of false positives is significant but well-established. To date, no randomised clinical study has been done to examine the effect of screening ultrasonography on breast cancer mortality rates. A whole breast ultrasound may enable doctors to screen for breast cancers that are not detectable by traditional mammography, especially in cases of dense breast tissue when mammography's sensitivity is lower. Breast ultrasound imaging provides information on the location and size of a tumour, as well as whether it is solid or fluid-filled and requires a biopsy to rule out cancer. This assessment is swiftly evolving into a standard process for identifying lumps in young ladies.

Single photon emission computerised tomography (SPECT)

This process makes use of gamma-ray-emitting single photon radionuclides, such as technetium-99 m, iodine-131, and gallium-67. For the organ of curiosity, it is a precise and effective scan. It can also be used on the full body, is safe in terms of radiation dosage expressions, and works well for identifying both primary and metastatic tumours. Thyroid cancer is indicated and treated with iodine-131 combined.

MRI and breast cancer

For many years, mammography has been accepted as a suitable screening technique for the identification of breast cancer; however, it is not able to differentiate between solid and cystic masses, and it may miss as many as 10-15% of cases. In contrast, magnetic resonance imaging (MRI) yields more precise results and is clearly beneficial to women who are developing breast cancer as a result of BRCA1 and BRAC2 genetic mutations and who also have axillary lymph adenopathy.

Breast biopsy

The gold standard method for detecting breast cancer is a breast biopsy. Breast biopsies come in a wide variety of forms. Concurrent breast imaging, clinical breast examination, and biopsy are done to improve diagnosis accuracy and eliminate as many false negative results as feasible (triple test).

Management

The goal of managing breast cancer is to maintain quality of life while extending survival. Utilising bioflavonoids could prevent the production of



oestrogen. Improving therapeutic outcomes is largely dependent on physicians and patients having effective communication. Effective communication between physicians and patients is beneficial, according to Oshima et al. According to a Japanese study, this kind of communication aids in the patients' ability to manage side effects. Breast cancer patients' quality of life is improved by doctor-patient contact. Less radiation exposure, a higher family monthly income, a longer time following diagnosis, more education, early stage disease, and younger age have all been linked to improved quality of life (QOL) in breast cancer patients, according to prior research.

Psychological readjusting to breast cancer

Breast cancer affects many women every year in both developed and developing nations, and it is a very frequent and distressing event. A picture of the emotional and social effects of breast cancer on women's lives, as well as variables associated with better or worse amendment, have been provided by psychological study. Psychosocial mediations have been beneficial in easing patients' bereavement and enhancing their quality of life. The results of this study suggest that psychological factors may also be connected to important biological processes that may be linked to medical conditions. In addition to providing insight into the psychological elements of breast cancer, research in this area has laid the groundwork for future studies on how people generally react to health-related stress.

Surgery

Lumpectomy

Surgery is a procedure that certain breast cancer patients must go through. The American Cancer Society states that a lumpectomy or partial mastectomy involves removing the portion of the breast that has a malignant tumour along with some surrounding lymph nodes and healthy tissues, keeping as much of the breast as possible intact. This technique is typically carried out on women who are in the early stages of their cancer; nevertheless, the patient also needs further treatment, such as hormone replacement therapy, chemotherapy, or radiation therapy, in addition to this procedure. Initially, most surgeons and patients would rather have a lumpectomy than a full breast excision, particularly if the woman is more worried about losing her breast.

Mastectomy

A mastectomy is performed to lower the chance of breast cancer developing. Although it reduces the

likelihood of breast cancer formation, bilateral preventive mastectomy does not totally remove the danger of cancer growth. It is thought that aromatase and tamoxifen are more beneficial than contralateral preventive mastectomy in reducing the incidence of contralateral breast cancer. When a lumpectomy was insufficient to address a diffuse case of breast cancer, a mastectomy is seen to be the most effective course of action. Nevertheless, the majority of women experience depression as a result of feeling asexual and losing their sense of self.

Chemotherapy

Chemotherapy is the procedure of eradicating cancer cells with specific medications. Depending on the patient's health, it might be administered both before and after surgery. Although secondary breast cancer, or metastatic breast cancer, is difficult to treat, it can be managed for a number of years. In order to control or slow the spread of metastatic breast cancer, chemotherapy may be recommended. Additionally, it can be used to lessen some symptoms. Chemotherapy may be started before or in addition to other forms of treatment.

Thermochemotherapy

When combined with chemotherapy, Medifocus heat management increased the median cancer shrinkage in the thermochemotherapy arm to 88.4%, while chemotherapy by itself only resulted in a median cancer shrinkage of 58.8%. About 80% of breast malignancies in the thermo-chemotherapy management arm had a cancer size drop of 80% or greater, compared to only 20% in the chemotherapy alone.

Conclusion

As our understanding of the pathophysiologic pathways behind breast cancer has grown, so too has the number of biomolecular markers. Furthermore, the field of targeted drug design has advanced rapidly and intricately, yielding a multitude of drugs that specifically target these markers for both in vivo research in animal models and human clinical trials. Scientists and doctors are excited about the expanding management strategies, but their enthusiasm is tempered by concern that there won't be enough funding to move the majority of these drugs through advanced clinical studies. Therefore, selecting the most effective drugs for further investigation and the appropriate clinical trials for these assessments provide obstacles. Our approach to identifying the most well-documented molecular targets in breast cancer is one



of justification. Up until now, drugs that alter the NRF have not undergone thorough evaluation. However, these investigations may increase the likelihood that genuine "endocrine" approaches to breast cancer treatment will be developed. Moreover, medicines that modify apoptosis and angiogenesis present an exciting field of study, primarily in carefully selected combination regimens.

Reference

1. Coleman M, Quaresma M, Berrino F, Lutz JM, Angelis R, Capocaccia R, et al. Cancer survival in five continents: a worldwide population-based study (CONCORD). *Lancet Oncol.* 2008;9:730–56.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. *CA Cancer J Clin.* 2013;63:11–30.
3. Berry D, Cronin K, Plevritis S, Fryback D, Clarke L, Zelen M, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. *N Engl J Med.* 2005;353:1784–92.
4. Reeder J, Vogel V. Breast cancer prevention. *Cancer Treat Res.* 2008;141:149–64.
5. Dwivedi V, Shrivastava R, Hussain S. Comparative anticancer potential of clove (*Syzygium aromaticum*)—an Indian spice—against cancer cell lines of various anatomical origin. *Asian Pac J Cancer Prev.* 2011;12(8):1989–93.
6. Mary J, Vinotha P, Pradeep A. Screening for in vitro cytotoxic activity of seaweed, *Sargassum* sp. against Hep-2 and MCF-7 cancer cell lines. *Asian Pac J Cancer Prev.* 2012;13:6073–6.
7. Han S, Guo Q, Wang T. Prognostic significance of interactions between ER alpha and ER beta and lymph node status in breast cancer cases. *Asian Pac J Cancer Prev.* 2013;14:6081–4.
8. Agnieszka M, Magdalena K, Grazyna J, Iwanowicz P. Assessment of midwifery student preparation for performing the role of breast cancer educator. *Asian Pac J Cancer Prev.* 2014;15:5633–8.
9. Hanif M, Zaidi P, Kamal S, Hameed A. Institution-based cancer incidence in a local population in Pakistan: 9 year data analysis. *Asian Pac J Cancer Prev.* 2009;10:227–30.
10. Moore M, Ariyaratne Y, Badar F. Cancer epidemiology in South Asia past, present and future. *Asian Pac J Cancer Prev.* 2009; 10:49–67.